SCHEMBL288292

SCHEMBL288292

OCCSc1ccc2c(c1)CCN2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
APP P05067 1/20 0.39
HRH3 Q9Y5N1 2/20 0.38
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
CA12 O43570 2/20 0.36
CA1 P00915 2/20 0.36
CA2 P00918 2/20 0.36
CA7 P43166 1/20 0.36
CA13 Q8N1Q1 1/20 0.36
ALDH1A1 P00352 4/20 0.35
ATM Q13315 1/20 0.35
ALOX15 P16050 2/20 0.34
GAA P10253 2/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
THRB P10828 1/20 0.34
CASP1 P29466 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3231505 0.84 DRD2 (0.46) DRD2DRD4APPHRH3MAPT
SCHEMBL3238873 0.81 DRD2 (0.44) DRD2DRD4APPHRH3MAPT
SCHEMBL3245294 0.80 DRD2 (0.49) DRD2DRD4APPHRH3MAPT
SCHEMBL8526813 0.77 DRD2 (0.57) DRD2DRD4APPHRH3MAPT
SCHEMBL3236359 0.76 DRD2 (0.45) DRD2DRD4APPHRH3MAPT
SCHEMBL3244192 0.76 DRD2 (0.45) DRD2DRD4APPHRH3MAPT
SCHEMBL31539406 0.75 MAOA (0.46) DRD2DRD4ALDH1A1ATMHSD17B10
SCHEMBL3231127 0.75 MAOA (0.41) DRD2DRD4APPHRH3ALDH1A1
SCHEMBL288350 0.74 DRD2 (0.53) DRD2DRD4APPHRH3MAPT
SCHEMBL27265657 0.74 DRD2 (0.53) DRD2DRD4APPHRH3MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427450-A1 GPR 119 MODULATORS Pfizer Inc. (US) 2012-03-14 EP disclosed
EP-2427448-A1 Gpr 119 modulators Pfizer Inc. (US) 2012-03-14 EP disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
US-20120052130-A1 GPR 119 MODULATORS PFIZER INC. 2012-03-01 US disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128414-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
WO-2010128425-A1 GPR 119 MODULATORS PFIZER INC. (US) 2010-11-11 WO disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed
US-20100285145-A1 GPR 119 MODULATORS PFIZER INC 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120052130-A1 GPR 119 MODULATORS GPR119, GPR39, GPR65 DRD2 1614/4885DRD4 3506/4885APP 2015/4885
US-20100285145-A1 GPR 119 MODULATORS GPR119, GPR65, GPR39 DRD2 1425/4885DRD4 3613/4885APP 2027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.